Core Viewpoint - He Yuan Bio (688765.SH) reported a significant increase in total operating revenue for the fiscal year 2025, driven by the successful market launch of its new product, Aofumin®, which was approved in July 2025 [1] Financial Performance - The company achieved total operating revenue of 478.614 million yuan, representing a year-on-year growth of 89.80% [1] - The net profit attributable to the parent company was a loss of 158 million yuan, compared to a loss of 151 million yuan in the same period last year [1] Product Development - The substantial revenue growth was primarily due to the rapid sales breakthrough of Aofumin® following its market approval [1] - Continuous market promotion and increasing recognition of the product's clinical value among end users contributed to the company's growth momentum [1]
禾元生物(688765.SH)2025年度归母净亏损1.58亿元